+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
ID06937086

Study of Mirikizumab With Tirzepatide or Placebo in Adults With Moderate to Severe Ulcerative Colitis and Obesity or Overweight

Led by Eli Lilly and Company · Updated on 2026-11-04

350

Participants Needed

186

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether combining mirikizumab with tirzepatide can reduce or eliminate symptoms of moderately to severely active ulcerative colitis UC and help participants lose at least 10% of their body weight. This phase 3b study focuses on adults with UC who are also obese or overweight, comparing treatment with mirikizumab plus tirzepatide against mirikizumab plus placebo. The study is sponsored by Eli Lilly and Company and aims to better understand treatment effects on UC symptoms and weight loss. Participants receive mirikizumab first by intravenous infusion, followed by subcutaneous injections of mirikizumab. They are randomly assigned to also receive either tirzepatide or a placebo via subcutaneous injection. Treatment lasts up to 52 weeks. The study is double-blinded, so neither participants nor researchers know who receives tirzepatide or placebo during the trial. Throughout the study, participants undergo regular monitoring including clinical assessments to evaluate remission and response of UC symptoms, endoscopic exams, and histologic evaluations. Researchers measure the percentage of participants who achieve both clinical remission and significant weight loss at week 52. The total participation time is up to 61 weeks, including screening and treatment. Safety and effectiveness are closely tracked during and after treatment.

CONDITIONS

Brief Title

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Research Team

T

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

P

Physicians interested in becoming principal investigators please contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here